Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
LeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Ascentage Pharma Group International (AAPG) Receivables - Other (2023 - 2025)

Ascentage Pharma Group International posted quarterly Receivables - Other of $205144.2 for Q4 2025, down 75.99% year-on-year from $854366.9 in Q4 2024, and down 75.99% on a QoQ basis from $854366.9 in Q4 2024.

Ascentage Pharma Group International (AAPG) has 3 years of Receivables - Other data on file, last reported at $205144.2 in Q4 2025.

  • For the quarter ending Q4 2025, Receivables - Other fell 75.99% year-over-year to $205144.2; the trailing twelve-month figure through Dec 2025 stood at $205144.2 (down 75.99% YoY), and the FY2025 full-year result was $208000.0, down 75.27% from the prior year.
  • Receivables - Other for Q4 2025 stood at $205144.2, down from $854366.9 in the prior quarter.
  • Across five years, Receivables - Other topped out at $921795.6 in Q4 2023 and bottomed at $205144.2 in Q4 2025.
  • The 3-year median for Receivables - Other is $854366.9 (2024), against an average of $660435.6.
  • The widest annual swing landed in 2024, when Receivables - Other slipped 7.31%; it then tumbled 75.99% in 2025.
  • A 3-year view of Receivables - Other shows it stood at $921795.6 in 2023, then declined by 7.31% to $854366.9 in 2024, then slumped by 75.99% to $205144.2 in 2025.
  • The last three Receivables - Other figures came in at $205144.2 (Q4 2025), $854366.9 (Q4 2024), and $921795.6 (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn
8 Evaxion A 65.44 Bn 65.42 Bn -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn
10 Ascentage Pharma Group International 1.11 Bn 937.28 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 205,144.23
Dec 31, 2025 205,144.23
Dec 31, 2024 854,366.87
Dec 31, 2024 854,366.87
Dec 31, 2023 921,795.63
Dec 31, 2023 921,795.63